All Insight, Analysis and Views

ViewPoints: Nektar's IO combo levels out at SITC

Ref: ViewPoints Desk

Tags: ViewPoints BMS Nektar Melanoma Clinical Research (R&D)SITC NKTR-214 Opdivo

ViewPoints: Expect China's drug innovation to have a global impact soon, predict experts

Ref: ViewPoints Desk

Tags: ViewPoints China Clinical Research (R&D) Corporate Affairs Marketing & Sales Regulatory Affairs

Physician Views: Is Amarin's REDUCE-IT study practice changing?

Ref: Physician Views Desk

Tags: Physician Views Amarin Dyslipidemia Clinical Research (R&D) Medical Affairs AHA Scientific Sessions Vascepa

ViewPoints: Object in Hemlibra’s rear mirror may be larger than it appears – or is it?

Ref: ViewPoints Desk

Tags: ViewPoints BioMarin Roche FDA Clinical Research (R&D) Marketing & Sales Medical Affairs Hemlibra valoctocogene roxaparvovec

ViewPoints: Voyager's voyage now looking slightly longer

Ref: ViewPoints Desk

Tags: ViewPoints Voyager Therapeutics Axovant Parkinson's FDA Clinical Research (R&D) Regulatory Affairs VY-AADC AXO-Lenti-PD

ViewPoints: Foamix endeavouring to snag a small slice of multiple markets

Ref: ViewPoints Desk

Tags: ViewPoints Foamix Acne FDA Clinical Research (R&D) Medical Affairs Regulatory Affairs FMX101 FMX103

ViewPoints: Oncology at heart of everything going right at AstraZeneca

Ref: ViewPoints Desk

Tags: ViewPoints AstraZeneca Breast Cancer Leukaemias Lung Cancer Ovarian Cancer Marketing & Sales Calquence Lynparza Tagrisso

Friday Five – the pharma week in review

Ref: Friday Five Desk

Tags: Friday Five Clinical Research (R&D) Corporate Affairs Marketing & Sales Regulatory Affairs

ViewPoints: Jazz reworks Vyxeos launch, but investors await the next best thing

Ref: ViewPoints Desk

Tags: ViewPoints Jazz Pharmaceuticals ImmunoGen Leukaemias Clinical Research (R&D) Corporate Affairs Marketing & Sales ASH Vyxeos Xyrem IMGN632

ViewPoints: Is Alnylam off course with Onpattro launch?

Ref: ViewPoints Desk

Tags: ViewPoints Alnylam Corporate Affairs Marketing & Sales Onpattro